Letter to the Editor:

Navigating our health care system is already challenging—and now, some elected officials are championing a deeply flawed proposal that would limit access to life-saving medications not only for Medicaid recipients, but for millions of Americans across our broader health care system.

As part of the federal Reconciliation package currently under debate, there is growing support for implementing a Most Favored Nation (MFN) policy for drug pricing. While intended to lower costs, this approach would instead impose significant operational burdens on pharmaceutical manufacturers, effectively functioning as an additional tax.

In a market-driven economy, increased costs in one area will inevitably lead to cuts in another. In this case, what’s at risk is not just business overhead—it’s patients’ access to essential treatments. Faced with punitive pricing structures, some companies may scale back innovation, restrict distribution, or opt out of Medicaid entirely.

The consequences would be far-reaching. Reduced participation in Medicaid would create dangerous coverage gaps for vulnerable populations. Moreover, the MFN model would have a chilling effect across the entire health care system, discouraging investment in research and development, delaying the introduction of breakthrough therapies, and destabilizing access to care for patients in both public and private insurance markets.

The Most Favored Nation policy moves our health care system in the wrong direction. It undermines access, innovation, and affordability. We urge our elected officials to reject this shortsighted proposal—and to prioritize solutions that expand access to care, rather than restrict it.

Betsy Huber

Lincoln University, Pa.